Cheshire drug maker Alexion Pharmaceuticals Inc. said it bought privately held biotechnology firm Taligen Therapeutics, of Aurora, Colo., for $111 million, to expand its product portfolio, Reuters reports.
Alexion said it will provide 2011 financial outlook in February, including deal-related expenses.
Adjusted research and development expenses for 2011 are expected to be about 18 percent of sales, including activities related with Taligen’s programs, Alexion said in a statement.
The deal also entails additional payments related to reaching various clinical efficacy and product approval milestones in both the United States and European Union for up to six products.
Alexion’s sole product, Soliris, treats a genetic blood disease called paroxysmal nocturnal hemoglobinuria, or PNH.
